Merck & Co., Inc. (NYSE:MRK) EVP Sells 6,050 Shares

Key Points

• Merck EVP Richard Deluca sold 6,050 shares at an average price of $130.38, generating proceeds of $788,799 and reducing his direct ownership by 3.75%.
• Merck reported quarterly revenue of $16.61 billion and adjusted earnings of $(0.13) per share, beating analyst expectations, while revenue increased 5.1% year over year. The company issued fiscal 2026 EPS guidance of $2.66–$2.76.
• Shares recently traded near $130.72, and analysts maintain a “Moderate Buy” consensus with an average price target of $134.56. Merck also declared a quarterly dividend of $0.85 per share, yielding approximately 2.6% annually.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Richard Deluca sold 6,050 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $130.38, for a total value of $788,799.00. Following the transaction, the executive vice president directly owned 155,487 shares of the company's stock, valued at approximately $20,272,395.06. The trade was a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock traded up $2.14 during trading on Monday, reaching $130.72. The company had a trading volume of 5,200,151 shares, compared to its average volume of 10,735,965. The firm's 50-day simple moving average is $123.98 and its 200 day simple moving average is $119.18. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05. The firm has a market capitalization of $322.85 billion, a PE ratio of 104.58, a price-to-earnings-growth ratio of 5.56 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is 272.00%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the 4th quarter valued at about $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Graney & King LLC raised its position in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after buying an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MRK. UBS Group lifted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Wall Street Zen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Barclays raised their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, CICC Research initiated coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price target for the company. Thirteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $134.56.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source